CORDIS
EU research results

CORDIS

English EN
MEDICIS-produced radioisotope beams for medicine

MEDICIS-produced radioisotope beams for medicine

Objective

Pure accelerated radioisotope beams have been used for 50 years in fundamental physics R&D, e.g. for nuclear structure studies (pear shaped exotic nuclei, Nature 2013); CERN-ISOLDE plays a central role in developing accelerator technologies and fostering collaborative approaches to advance this field of isotope mass separation online. Our most recent contribution was the use of nanomaterial targets for more intense and reliable beam production, and laser ion sources for their purification (discovery of yet unknown 233Francium).
Radioisotopes are widely used for functional imaging in medicine, based on 99mTechnetium or on 18Fluorine. This field is expected to rapidly expand, when coupling imaging with new cancer treatments, with isotopes emitting different type of radioactivity, e.g. alpha particles. This is shown with the recently introduced 223Radium chloride (Xofigo®) used as a treatment drug in advanced bone cancers. However, either shortage in the supply of 99mTechnetium or lack of access to new radioisotope with adequate properties is a severe treat to develop personalized treatment that combine functional imaging and therapy.
Ovarian cancers have poor prognosis, are the second most frequent cancer for women and one of the deadliest. They are difficult to treat, because of possible presence of metastasis, and because this region is difficult to irradiate without collateral damages.
MEDICIS-PROMED will train a new generation of scientists to develop systems for personalized Medicine combining functional imaging and treatments based on radioactive ion beam mass-separation. This will be done across a coherent intersectorial multidisciplinary network with world-leading scientists in their field.
Subsystems for the development of new radiopharmaceuticals, of isotope mass separators at medical cyclotrons, and of mass separated 11Carbon for PET-aided hadron therapy will be specifically developed to treat the ovarian cancer.

Coordinator

EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

Address

Route De Meyrin Cern
1211 Geneva 23

Switzerland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 795 680,28

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 273 287,88

JOHANNES GUTENBERG-UNIVERSITAT MAINZ

Germany

EU Contribution

€ 249 216,48

Advanced Accelerator Applications

France

EU Contribution

€ 262 875,60

INSTITUTO SUPERIOR TECNICO

Portugal

EU Contribution

€ 476 712,72

FONDAZIONE CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA

Italy

EU Contribution

€ 258 061,32

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 250 560

LEMER PAX

France

EU Contribution

€ 262 875,60

Partners (7)

Sort alphabetically

Expand all

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

LES HOPITAUX UNIVERSITAIRES DE GENEVE

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

EBG (Entwicklungs- und Betriebsgesellschaft) MedAustron GmbH

GROUPEMENT INTERET PUBLIC ARRONAX

INSTITUT MAX VON LAUE - PAUL LANGEVIN

Isis Innovation Ltd

Project information

Grant agreement ID: 642889

Status

Closed project

  • Start date

    1 April 2015

  • End date

    31 March 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 829 269,88

  • EU contribution

    € 2 829 269,88

Coordinated by:

EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

Switzerland